Receptor News and Research

RSS

Scientists create new way to study brain function

Scientists at Duke University and the University of North Carolina have devised a chemical technique that promises to allow neuroscientists to discover the function of any population of neurons in an animal brain, and provide clues to treating and preventing brain disease.

15 Jul 2009

Discovery of key protein for tumor suppression in ER+ breast cancer

Researchers from the Kimmel Cancer Center at Jefferson have identified a protein relationship that may be an ideal treatment target for ER+ breast cancer. The study was reported in the July 15 issue of Cancer Research.

15 Jul 2009

Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Schering-Plough Corporation has announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. In this study, vicriviroc is being evaluated in a novel nucleoside-sparing regimen that is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment.

15 Jul 2009

Innovative study brings us closer to an explanation for Crohn's disease

Twenty-five per cent of Crohn's disease patients have a mutation in what is called the NOD2 gene, but it is not precisely known how this mutation influences the disease.

9 Jul 2009

Study may lead to new drugs to treat cough

Scientists investigating the cough reflex have discovered a new group of molecules on the surface of nerve cells that make us cough when irritated.

9 Jul 2009

Senior breast cancer patients receive ‘chemo’ if treated in private practices

In a study to determine the non-medical factors that may be associated with the decision to treat nonmetastatic breast cancer, researchers at Columbia University Mailman School of Public Health evaluated the association between oncologist characteristics and the receipt of chemotherapy in elderly women with breast cancer and found that they were more likely to receive chemotherapy if treated by oncologists employed in a private practice.

7 Jul 2009

Potential new target for acute myeloid leukemia

Dr. John Dick, Senior Scientist at the Ontario Cancer Institute, the research arm of Princess Margaret Hospital, co-led a multinational team that has developed the first leukemia therapy that targets a protein, CD123, on the surface of cancer stem cells that drive acute myeloid leukemia (AML), which is an aggressive disease with a poor outcome.

6 Jul 2009

Newly discovered gene regulates balance of 'bad' cholesterol

In an article in Science, Noam Zelcer from the LACDR describes a previously unknown mechanism for regulating the amount of LDL cholesterol. This offers opportunities for supplementing and improving the effect of so-called statins: medicines that remove 'bad' cholesterol from the bloodstream.

30 Jun 2009

Stomach hormone ghrelin may lead to new treatments for alcohol dependence

Researchers at the Sahlgrenska Academy, Gothenburg, have discovered a new brain mechanism involved in alcohol addiction involving the stomach hormone ghrelin. When ghrelin’s actions in the brain are blocked, alcohol’s effects on the reward system are reduced. It is an important discovery that could lead to new therapies for addictions such as alcohol dependence.

30 Jun 2009

Early detection of pancreatic cancer closer thanks to multifunctional nanoparticles

Pancreatic cancer has a devastatingly low survival rate (less than 5 percent after 5 years) because it is usually diagnosed at an advanced stage. The initial symptoms, such as pain, jaundice, or weight loss, often do not allow the disease to be caught early enough for surgery and chemotherapy to be effective.

28 Jun 2009

ADHD genes found - missing DNA segments may suggest future drug targets

Pediatric researchers have identified hundreds of gene variations that occur more frequently in children with attention-deficit hyperactivity disorder (ADHD) than in children without ADHD. Many of those genes were already known to be important for learning, behavior, brain function and neurodevelopment, but had not been previously associated with ADHD.

24 Jun 2009

New biomarker predicts brain tumor's response to cediranib therapy

A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib.

23 Jun 2009

A new take on growth factor signaling in tamoxifen resistance

Differences in growth factor (GF) signaling may cause the poor prognosis in some breast cancer cases. A new study, published in the open access journal BMC Medical Genomics, suggests that some estrogen receptor-positive breast cancers respond poorly to tamoxifen because of increased GF signaling.

23 Jun 2009

Cryo-electron tomography shows immature HIV in 3D

Scientists at the European Molecular Biology Laboratory (EMBL) and the University Clinic Heidelberg, Germany, have produced a three-dimensional reconstruction of HIV (Human Immunodeficiency Virus), which shows the structure of the immature form of the virus at unprecedented detail. Immature HIV is a precursor of the infectious virus, which can cause AIDS.

23 Jun 2009

Researchers develop promising new breast cancer diagnostic marker

Indiana University School of Medicine researchers have developed a new breast cancer diagnostic marker that could enable physicians to more easily determine which patients have a less aggressive form of the disease that may not require chemotherapy treatment.

21 Jun 2009

Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise

Antisense Therapeutics Ltd. (ASX: ANP) has reported further positive results from its collaborative preclinical research studies on the therapeutic potential of ATL1101 in prostate cancer. In experimental models, ATL1101 treatment significantly enhanced the tumor-suppressive effect of the cancer drug Paclitaxel. Paclitaxel is one of a class of drugs known as taxanes.

18 Jun 2009

Circadian Technologies granted significant European patent

Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.

17 Jun 2009

Discovery of genetic markers to help fight diabetes

Translational Genomics Research Institute (TGen) scientists have identified five genetic biomarkers that could help lead to improved treatments, with fewer side-effects, for patients with diabetes.

17 Jun 2009

Histamine affects alcohol-related behaviour

The histamine-3 receptor is important in terms of alcohol-related behaviour, and a drug affecting that receptor may have qualities that alter alcohol-related behaviour.

16 Jun 2009

Immune system’s role in breast cancer

Researchers working with Dr Marcus Schmidt in the Department of Obstetrics and Gynecology at the University Medical Center Mainz have unlocked the key to the immune system's significance in cases of breast cancer, thus identifying its long-neglected role in the prognosis of the disease.

16 Jun 2009